Asim Pervaiz1,2, Talha Saleem3,4, Kinzah Kanwal3, Syed Mohsin Raza3, Sana Iqbal5, Michael Zepp6,7, Rania B Georges6,8, Martin R Berger6,7. 1. Institute of Biomedical and Allied Health Sciences, University of Health Sciences, Lahore, Pakistan. drasimpervaiz@uhs.edu.pk. 2. Toxicology and Chemotherapy Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany. drasimpervaiz@uhs.edu.pk. 3. Institute of Biomedical and Allied Health Sciences, University of Health Sciences, Lahore, Pakistan. 4. Department of Allied Health Sciences, Superior University, Lahore, Pakistan. 5. Human Genetics and Molecular Biology Department, University of Health Sciences, Lahore, Pakistan. 6. Toxicology and Chemotherapy Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany. 7. Immundiagnostik, Bensheim, Germany. 8. Coordination Centre for Clinical Trials, University Hospital, Heidelberg, Germany.
Abstract
BACKGROUND: Ectopic expression of anticancer genes (ACGs) imposes antineoplastic effects on transformed cells. Clinically, reduced expression of these genes has been linked with poor prognosis, metastasis and chemo/radiotherapy resistance in cancers. Identifying expression pattern of ACGs is crucial to establish their prognostic and therapeutic relevance in colorectal cancer (CRC). In addition to the clinical perspective, naturally occurring compounds can be explored in parallel for inducing ACGs to achieve cancer cell-specific death. METHODOLOGY: Expression profiles of three ACGs (NOXA, PAR-4, TRAIL) were identified via real-time PCR in CRC clinical isolates. Time lapse-based expression modifications in ACGs were studied in a CRC liver metastasis animal model using microarray methodology. Effects of a purified plant protein (riproximin) on selected ACGs were identified in three primary and metastatic CRC cell lines by real-time PCR. Lastly, importance of the ACGs in a cellular environment was highlighted via bioinformatic analysis. RESULTS: ACGs (except NOXA) were persistently downregulated in clinical isolates when comparing the overall mean expression values with normal mucosa levels. In vivo studies showed a prominent inhibition of NOXA and PAR-4 genes in implanted CRC cells during rat liver colonization. TRAIL showed deviation from this theme while showing marked induction during the early period of liver colonization (days 3 and 6 after CRC cell implantation). Riproximin exhibited substantial potential of inducing ACGs at transcriptome levels in selected CRC cell lines. Bioinformatic analysis showed that vital molecular/functional aspects of a cell are associated with the presence of ACGs. CONCLUSION: ACGs are downregulated in primary and metastatic phase of CRC. Riproximin effectively induces ACGs in CRC cells and can be exploited for clinical investigations over time.
BACKGROUND: Ectopic expression of anticancer genes (ACGs) imposes antineoplastic effects on transformed cells. Clinically, reduced expression of these genes has been linked with poor prognosis, metastasis and chemo/radiotherapy resistance in cancers. Identifying expression pattern of ACGs is crucial to establish their prognostic and therapeutic relevance in colorectal cancer (CRC). In addition to the clinical perspective, naturally occurring compounds can be explored in parallel for inducing ACGs to achieve cancer cell-specific death. METHODOLOGY: Expression profiles of three ACGs (NOXA, PAR-4, TRAIL) were identified via real-time PCR in CRC clinical isolates. Time lapse-based expression modifications in ACGs were studied in a CRC liver metastasis animal model using microarray methodology. Effects of a purified plant protein (riproximin) on selected ACGs were identified in three primary and metastatic CRC cell lines by real-time PCR. Lastly, importance of the ACGs in a cellular environment was highlighted via bioinformatic analysis. RESULTS: ACGs (except NOXA) were persistently downregulated in clinical isolates when comparing the overall mean expression values with normal mucosa levels. In vivo studies showed a prominent inhibition of NOXA and PAR-4 genes in implanted CRC cells during rat liver colonization. TRAIL showed deviation from this theme while showing marked induction during the early period of liver colonization (days 3 and 6 after CRC cell implantation). Riproximin exhibited substantial potential of inducing ACGs at transcriptome levels in selected CRC cell lines. Bioinformatic analysis showed that vital molecular/functional aspects of a cell are associated with the presence of ACGs. CONCLUSION: ACGs are downregulated in primary and metastatic phase of CRC. Riproximin effectively induces ACGs in CRC cells and can be exploited for clinical investigations over time.
Authors: Helene Bayer; Katharina Essig; Sven Stanzel; Martin Frank; Jeffrey C Gildersleeve; Martin R Berger; Cristina Voss Journal: J Biol Chem Date: 2012-08-07 Impact factor: 5.157
Authors: P Bruno; C R Brinkmann; M-C Boulanger; M Flinterman; P Klanrit; M-C Landry; D Portsmouth; J Borst; M Tavassoli; M Noteborn; C Backendorf; R M E Zimmerman Journal: Cell Death Differ Date: 2009-01 Impact factor: 15.828
Authors: James V Alvarez; Tien-Chi Pan; Jason Ruth; Yi Feng; Alice Zhou; Dhruv Pant; Joshua S Grimley; Thomas J Wandless; Angela Demichele; Lewis A Chodosh Journal: Cancer Cell Date: 2013-06-13 Impact factor: 31.743
Authors: Hassan Adwan; Ahmed Murtaja; Khamael Kadhim Al-Taee; Asim Pervaiz; Thomas Hielscher; Martin R Berger Journal: Cancer Biol Ther Date: 2014-06-11 Impact factor: 4.742
Authors: G AbuAli; W Chaisaklert; E Stelloo; E Pazarentzos; M-S Hwang; D Qize; S V Harding; A Al-Rubaish; A J Alzahrani; A Al-Ali; T A B Sanders; E O Aboagye; S Grimm Journal: Oncogene Date: 2014-04-28 Impact factor: 9.867
Authors: Ravshan Burikhanov; Nikhil Hebbar; Sunil K Noothi; Nidhi Shukla; James Sledziona; Nathália Araujo; Meghana Kudrimoti; Qing Jun Wang; David S Watt; Danny R Welch; Jodi Maranchie; Akihiro Harada; Vivek M Rangnekar Journal: Cell Rep Date: 2017-01-10 Impact factor: 9.423